Physician profile

Marisa Gefen

Internal Medicine · Philadelphia, PA

NPI 1386846806

$757.81

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$85.15

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $301.72 2019-2021
Astellas Pharma US INC $175.50 2019-2021
Novo Nordisk INC $71.12 2020-2022
Abbott Laboratories $58.35 2024 Freestyle Libre 3
Sunovion Pharmaceuticals INC. $47.36 2019
Astrazeneca Pharmaceuticals LP $27.98 2020
Dexcom, INC. $26.80 2023 Dexcom G6 Transmitter
Bayer Healthcare Pharmaceuticals INC. $18.55 2021
Amarin Pharma, INC. $17.74 2019
E.R. Squibb & Sons, L.L.C. $12.69 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Marisa Gefen

$757.81

in general payments reported 2019-2025

Years
2019-2024
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/154039/marisa-gefen

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.